Myxomycete communities occurring in fragmented forest patches in two municipalities of Laguna, Philippines

In spite of the increasing number of myxomycete studies in the tropical Southeast Asia over the last decades, many forest patches are still left unexplored for the region, in particular in the Philippine archipelago. Thus, an assessment of myxomycete diversity, occurrence, and composition was carried out in forest fragments from two municipalities of the province of Laguna, Philippines. From the 12 established 5 m × 5 m plots, a total of 240 moist chamber cultures were prepared for this study and yielded 42 myxomycete species belonging to 14 genera. Rarefaction curves and several heterogeneity indices revealed higher species diversity in Los Baños than in Calauan. Moreover, the taxonomic diversity index also showed that the taxonomic diversity of myxomycete in Los Baños is more intuitively diverse than in Calauan. In terms of community analysis between the two municipalities, it showed that myxomycete communities clustered between different microhabitats. High values of coefficient of community and percentage similarity indices possibly implicates that spore dispersal in forest fragments in closer proximities may cause high number of shared species (60%). With an addition of Cribraria lepida as a new record for the country, this study now updates the myxomycete profile for Laguna, Philippines

Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: The introduction of a new measure

Item does not contain fulltextPURPOSE: To investigate the impact of chemotherapy-induced neurotoxicity on daily activities and quality of life (QoL) of cancer patients. METHODS: QoL of all patients visiting the oncological outpatient ward of the Maxima Medical Centre in the Netherlands from October 2006 until March 2007 treated with taxanes, vinca-alkaloids and/or platinum compounds (n = 88) was compared with the QoL of patients that did not receive these treatments yet (n = 43). Patient-reported neuropathy symptoms were evaluated with the newly developed Chemotherapy Induced Neurotoxicity Questionnaire (CINQ) and the Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group/Neurotoxicity (FACT/GOG-Ntx) questionnaire. RESULTS: Patients treated with chemotherapy reported significantly more complaints of neuropathy (p < 0.001) and more paresthesias and dysesthesias in the upper (p < 0.001; p < 0.01) and lower extremities (p < 0.001) compared to those not treated with chemotherapy. They additionally experienced problems with fine motor function (e.g., getting (un)dressed, writing, and picking up small objects). Moreover, cold-induced paresthesias were frequently reported. Overall, patients indicated that their neuropathy had a negative effect on QoL. CONCLUSIONS: The newly developed CINQ and the FACT/GOG-Ntx results suggest a considerable negative impact of patient-reported neuropathy symptoms on daily activities and QoL in cancer patients treated with chemotherapy. However, further validation of the CINQ is needed

Expression of lysophosphatidic acid acyltransferase beta (LPAAT-β) in ovarian carcinoma: correlation with tumour grading and prognosis

Lysophosphatidic acid acyltransferase beta (LPAAT-β) is an enzyme involved in lipid biosynthesis whose role in tumour progression has been of emerging interest in the last few years. We investigated the expression of LPAAT-β by reverse transcriptase–polymerase chain reaction and immunohistochemistry in 10 ovarian cell lines as well as in a cohort of 106 ovarian tumours and normal ovaries. Lysophosphatidic acid acyltransferase beta mRNA was found in all cell lines and ovarian tumours examined. Expression of LPAAT-β protein was significantly increased in ovarian carcinomas compared to benign ovarian tissue (χ2 test P-value=0.001, Kruskal–Wallis test P-value <0.0001). Furthermore, LPAAT-β expression was positively associated with higher tumour grade (P=0.044), higher mitotic index (P<0.0001) and tumour stage (P=0.032). Expression of LPAAT-β was significantly linked to reduced overall survival time (P=0.024) as well as to shorter progression-free survival time (P=0.012) in patients younger than 60 years. Our study shows that LPAAT-β is upregulated in ovarian cancer and is more prevalent in poorly differentiated tumours. In addition, LPAAT-β expression is a predictor of a worse prognosis in patients younger than 60 years. Further studies are needed to investigate if LPAAT-β may serve as a therapeutic target for certain subgroups of patients